October 28, 2023 

Times posted in Eastern Time Zone

Session 1
9:00 AM – Introduction and overview of the day
9:06 AM – What to know about using electronic health record data
Jason Hsu
9:12 AM – Ins and outs of specific EHR databases
Thomas Ciulla
9:18 AM – Sight Outcomes Research Collaborative (SOURCE)
Josh Stein
9:24 AM – Ins and outs of specific claims databases
Sophia Wang
9:30 AM – Panel discussion

Session 2: Neovascular Age-Related Macular Degeneration
9:40 AM – Key Findings from the Voyager Study
Veeral Sheth
9:46 AM – Injection frequency and VA outcomes in exudative AMD
Andrew Moshfeghi
9:52 AM – The TRUCKEE study real world efficacy and safety of faricimab in neovascular AMD
Michael Singer
9:58 AM – Characteristics and outcomes of nAMD patients managed in US routine clinical practice: analysis of the IRIS registry database
Anita Barikian
10:04 AM – FARETINA studies
Ferhina Ali
10:10 AM – Panel discussion
10:25 AM – Break

Session 3: Applied Methods
10:27 AM – Picking an index date for your study design
Brian VanderBeek
10:33 AM – Use of RWD to augment clinical trials
Durga Borkar
10:39 AM – Considerations for using real world visual acuity in clinical outcomes research
Michael Mbagwu
10:45 AM – Adoption of ocular imaging standards
Zhongdi Chu
10:51 AM – Use of Unstructured Data in RWD Studies (Primer on NLP)
Cathy Sun
10:57 AM – Considerations for using real world images to create AI/ML algorithms
Aaron Lee
11:03 AM – Panel discussion
11:18 AM Break and Sponsor Presentation

Session 4: Retinovascular Disease
11:26 AM – Treatment Patterns and 5-Year Visual Acuity Outcomes in Patients With Retinal Vein Occlusion: Analysis of a Real-World Database From the US
Michael Ip
11:32 AM – Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
Thomas Ciulla
11:38 AM – The effect of loading doses on real world DME treatment outcomes
Blanche Kuo
11:44 AM – Real world outcomes of sustained steroids for DME
Jorge Fortun
11:50 AM – Impact of initial monthly doses of aflibercept on visual outcomes in eyes with diabetic macular edema in routine clinical practice in the US
Nitish Mehta
11:56 PM – Panel discussion
12:11 PM Break and Sponsor Presentation

Session 5: Non-Neovascular Age related Macular Degeneration
12:20 PM – Assessment of Geographic Atrophy in an intermediate AMD population
(VEGF) for retinal vein occlusions in the AAO IRIS® registry
Aleksandra Rachistaka
12:26 PM – Conversion rates of non-neovascular AMD to neovascular AMD
Dan Gong
12:32 PM – Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy
12:38 PM – Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
Theodore Leng
12:44 PM – Panel discussion
1:00 PM – Meeting adjourns